Menu
Synergy in Action

2013 Autumn Conference

30 September – 02 October, 2013   //   Philadelphia, PA, USA

Poster Awardees

Retrospective Review of Safety and Tolerability of Continuous Cerebrospinal fluid (CSF) Collections During Phase 1 Studies in Healthy Volunteers and Patients (B English)
Prefrontal GABA Abnormalities Associated With Reduced Hippocampal Volume In Major Depressive Disorder (C Abdallah)
All Poster Abstracts are available at the end of the second day

30 September 2013

Concurrent Workshops  
  Adaptive Design G Haynes
Report Back
  Addressing Methodological Challenges in International CNS Clinical Trials R Keefe
A Kalali
Report Back
  Biomarkers – The Advantage and Challenges of Sharing Biomarkers Data S Potkin
L Alphs
Report Back
  Options and Methods to Improve Cognitive Assessment in Clinical Trials of AD and Its Precursors H Posner
P Harvey
Workshop Slides:

Posner/Harvey
Loewenstein
Edland
Bastings
Report Back
  Initiating Innovation in CNS Clinical Trials G Sachs
Report Back
  Negative Symptoms S Marder
D Daniel

Daniel
Dunayevich
Report Back
  Suicidal Ideation and Behavior A Butler
P Chappell

Report Back
   

1 October 2013

Presidential Welcome

R Keefe
Slides
video

A Return to Rational CNS Drug Development: De-Risking Phase 3 Investments
Through Rigorous Early Phase Drug Evaluations
Session Chairs:
S Romano
R Keefe
  Session Introduction S Romano
Slides
video
  Part 1: Translational and Early Development Strategies and Tools Chairs:
D Feltner
W Potter
  Translational Pharmacology (‘Proof of Mechanism’): A Basic Model and Variations on a Theme W Potter
Slides
video
D Feltner
Slides
video
  Examples of Go and No-Go Decisions after Rigorous Early Phase Drug Evaluation G J Groeneveld
Slides
video
  Use of Exposure Response Modeling in Early Development S Riley
Slides
video
  Conducting the “Right” POC Study M Egan*
  Optimizing Phase II: Setting the Stage for Phase III Success C Mallinckrodt
Slides
video
  Discussion Panel Feltner/Potter
Video of panel discussion found at end of Mallincrodt video
  Part 2: Designing the Right Series of Experiments
Introduction
Chairs:
G Sachs
A Mahableshwarkar

Slides
video
  What Would We Consider Doing Differently: Lessons from the mGluR2/3 Agonist Schizophrenia Program B Kinon
Slides
video
  A Study to Delay the Onset of Mild Cognitive Impairment S Brannan
Slides
video
  Targeting Ventral Striatal Activation and Anhedonia in Early Phase Clinical Trials of Mood and Anxiety Spectrum Disorders: The NIMH FAST-MAS Perspective A Krystal
Slides
video
  The Pharmacological Characteristics of a Therapeutically Active Dose of Two First-in-class Drugs: Amorexant (ORX1/2-antagonist) and Rimonabant (CB1-antagonist) J van Gerven
Slides
video
  Panel Discussion Sachs / Mahableshwarkar
video
Poster Session/Reception Poster Abstracts

2 October 2013

  Part 3: Operational Challenges Chairs:
A Kalali
C Canuso
  Introduction A Kalali
  Operational Challenges: Novel Designs V Dragalin
Slides
  Novel Indications: Experiences from a Study in Mixed Depression J Cucchiaro
Slides
video
  Novel Indications: Challenges of Identification and Assessment of the Target Population: Experiences from a Study in Anxious Depression Daly
Slides
video
  Novel Outcome Measures: Standardization of Biomarker Endpoints – Examples from Studies of Schizophrenia and Alzheimer’s Disease S Potkin
Slides
video
  Panel Discussion Kalali / Canuso
video inludes Keefe closing
Closing R Keefe
Meeting Adjourns  
* Slide Presentations not released